Distribution and excretion of teicoplanin in rats after single and repeated intravenous administration.

Eur J Drug Metab Pharmacokinet

Istituto Ricerche Biomediche A. Marxer, Torino, Italy.

Published: August 1992

After the i.v. administration of a single 10 mg/Kg dose of [14C] teicoplanin to rats, no substantial differences were found between males and females as regards the hematic profile, the excretion pattern and tissue distribution. About 74% of the administered radioactivity was recovered in the 0-120 hours interval and more than 90% of this amount was found in the first 24 hours. In the 0-120 hour interval, 7% of the dose was excreted with the faeces, while the total 14C excreted (including the cage washing) was 82% of the dose. A high affinity of [14C] teicoplanin for the kidneys and especially for the cortex area was displayed in the distribution study. Similar findings were observed when 7 intravenous doses (10 mg/Kg each) were given to male rats at 24 hour intervals. The percentage of the total dose found in urine seven days after the last administration remained close to 70% and also the excretion data observed in each collection interval after the last treatment were comparable with those obtained in the single dose study. The distribution in tissues was very similar to that of the single dose experiment. The high 14C concentration level found in the kidneys of animals killed at 5 min after the last treatment was cleared with a disappearance rate comparable with that observed in the single dose experiment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

single dose
12
teicoplanin rats
8
[14c] teicoplanin
8
dose experiment
8
dose
7
single
5
distribution
4
distribution excretion
4
excretion teicoplanin
4
rats single
4

Similar Publications

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes.

Int J Retina Vitreous

January 2025

Fondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Avenue de France 54, Lausanne, 1001, Switzerland.

Background: This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month.

Methods: A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed.

View Article and Find Full Text PDF

Background: Transient receptor potential cation channel subfamily V member 2 (TRPV2) functions as a stretch-sensitive calcium channel, with overexpression in the sarcolemma of skeletal and cardiac myocytes leading to detrimental calcium influx and triggering muscle degeneration. In our previous pilot study, we showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide levels in two patients with muscular dystrophy and advanced heart failure. Building on this, we performed a single-arm, open-label, multicenter study herein to evaluate the safety and efficacy of tranilast in the treatment of advanced heart failure in patients with muscular dystrophy.

View Article and Find Full Text PDF

Background: Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2, causing constitutive activation of the kinase and activation of downstream signalling.

View Article and Find Full Text PDF

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Background: The KDIGO recommendation in acute kidney injury (AKI) patients requiring kidney replacement therapy is to deliver a Urea Kt/V of 1.3 for intermittent thrice weekly hemodialysis, and an effluent volume of 20-25 ml/kg/hour when using continuous renal replacement therapy (CRRT). Considering that prior studies have suggested equivalent outcomes when using CRRT-prolonged intermittent renal replacement therapy (PIRRT) effluent doses below 20 mL/kg/h, our group investigated the possible benefits of low effluent volume CRRT-PIRRT (12.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!